ClinicalTrials.gg
CompletedNCT00807495Updated Mar 27, 2018Results posted

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

A Phase 2 interventional study of Alisertib in Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma and Burkitt's Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-27.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 217 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Enrollment
383rd of 963
48 · median 37
Started
2009
with 30 others
Phase 2
380 of 1,131
47 open now
Registered
481st of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 383rd largest by enrollment of the 963 interventional ones that give a count, is one of 31 that started in 2009, is one of 380 in phase 2, and was the 481st registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.

Read the detailed description

The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have relapsed or refractory non-Hodgkin's lymphoma (NHL). The study looked at anti-tumor activity in participants who received alisertib.

The study enrolled 48 patients. Participants were categorized as per disease subtypes into five subtypes: Large B-Cell lymphoma, mantle cell lymphoma, transformed follicular lymphoma, Burkitts lymphoma and aggressive T-Cell lymphoma (Note: There were no participants enrolled with Precursor B-lymphoblastic Leukemia/Lymphoma). Participants received:

  • Alisertib 50 mg BID on Days 1 to 7

All participants took alisertib capsules approximately every 12 hours each day for 7 days followed by a 14-day rest period in a 21-days cycle. MLN8237 was supplied in capsules of 5 or 25 mg strength.

This multi-center trial was conducted in United States. The overall time to participate in this study was until there is evidence of disease progression or unacceptable treatment-related toxicity. If the participant would derive benefit from continued alisertib treatment beyond 24 months, the Sponsor was consulted for approval of further treatment. Participants made multiple visits to the clinic, with imaging assessments every 12 weeks. Participants discontinuing treatment prior to disease progression continue with clinic visits, chemistry and hematology lab testing, and tumor assessments every 12 weeks up to 12 months after last dose of study drug for follow-up assessments.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma
  • Mantle Cell Lymphoma
  • Burkitt's Lymphoma
  • T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma
  • Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component

Keywords

  • MLN8237
  • Alisertib
  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

  1. Participant must have histological or cytological diagnosis of a hematological of the following types that has or was refractory to prior therapy:

    • Diffuse large B-cell lymphoma
    • Mantle cell lymphoma
    • Burkitt's lymphoma
    • Precursor B-lymphoblastic leukemia/lymphoma
    • T-cell lymphoma, excluding primary cutaneous T-cell lymphoma
    • Transformed follicular lymphoma with ≥ 50% diffuse large cell component.
  2. Male or female participants 18 years or older.
  3. (ECOG) performance status 0-2.
  4. .

Exclusion criteria include the following:

  1. Pregnant or lactating females.
  2. Known (HIV) positive or AIDS-related illness.
  3. Any serious medical or psychiatric illness that could interfere with the completion of treatment.
  4. Total ≥ 1.5 × the (ULN).
  5. (ALT) and aspartate aminotransferase (AST) ≥ 2.5 × the ULN. AST, ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to their underlying hematological disorder.
  6. (ANC) \< 1,250/mm\^3.
  7. count \< 75,000/mm\^3.
  8. Calculated \< 30 mL/minute.
  9. stem cell transplant less than 6 months prior to enrollment.
  10. Participants who have undergone allogeneic stem cell or organ transplantation.
  11. Systemic antineoplastic therapy including (> 15 mg prednisone/day or equivalent), or treatment with an agent within 14 days preceding the first dose of study drug treatment.
  12. Participants who have received treatment with nitrosoureas, mitomycin C, rituximab, alemtuzumab, or other unconjugated antibody treatment, within 12 weeks prior to first dose.
  13. Participants who have received treatment with radioimmunoconjugates or within 12 weeks prior to first dose.
  14. Participants who have received radiotherapy within 21 days prior to first dose.
  15. Myocardial infarction within 6 months of enrollment or current history of (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
  16. Major surgery within 14 days prior to the first dose.
  17. Infection requiring systemic antibiotic therapy within 14 days prior to the first dose or other serious infection.
  18. Clinically uncontrolled central nervous system (CNS) involvement.
  19. Inability to swallow capsules.
  20. History of uncontrolled sleep apnoea syndrome and other conditions that could result in excessive daytime sleepiness (eg, - COPD).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Alisertib 50 mg

    Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 24 months or longer with Sponsor approval).

    Drug: Alisertib

Interventions

  • Alisertib capsules

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria)

    Best overall response rate is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the Investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites (as specified in the Cheson 2007, IWG response criteria).

    Time frame: Baseline and every 2 cycles up to Month 12 (approximately 16 cycles), from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months from last dose (Up to 4 years)

Secondary outcomes

  1. Time to Progression (TTP)

    Time to progression (TTP) is defined as the time in days from the date of first study drug administration to the date of first documentation of Progressive Disease (PD) according to IWG criteria (Cheson 2007). PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.

    Time frame: Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years)

  2. Progression Free Survival (PFS)

    PFS is defined as the time in days from the date of first study drug administration to the date of first documentation of progressive disease (PD) or death.

    Time frame: Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years)

  3. Duration of Response (DOR)

    DOR is defined as the time from the date of first documentation of a CR, or partial response (PR) to the date of first documentation of PD according to IWG criteria. CR definition includes the complete disappearance of all evidence of disease, the definition of PR includes at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses, and PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir, as described in the IWG response criteria (Cheson 2007).

    Time frame: Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years)

  4. Number of Participants With Treatment-Emergent Adverse Events

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and includes all-causality (ie, treatment-related and not treatment-related as assessed by the investigator).

    Time frame: First dose of study drug to 30 days after last dose (Up to 25 months)

  5. Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events

    Vital signs (blood pressure, heart rate, and oral temperature) measurements were obtained throughout the study. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: First dose of study drug to 30 days after last dose (Up to 25 months)

  6. Number of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events

    Abnormal laboratory values for chemistry or hematology tests that were assessed by the investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE V4). A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: First dose of study drug to 30 days after last dose (Up to 25 months)

07

Results

Posted Mar 27, 2018

Participant flow

Participants took part in the study at 12 investigative sites in the United States from 10 February 2009 to last participant off study 13 February 2013, with a data cut-off on 04 January 2011 to report the primary endpoint.

Participant flow — Overall Study
MilestoneAlisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)
Started2213517
Completed147102
Not completed86415
Withdrew: Adverse event63112
Withdrew: Withdrawal by patient20100
Withdrew: Reason not specified03203

Outcome measures

PrimaryBest Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria)

Best overall response rate is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the Investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites (as specified in the Cheson 2007, IWG response criteria).

Time frame:
Baseline and every 2 cycles up to Month 12 (approximately 16 cycles), from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months from last dose (Up to 4 years)
Reported as:
Number · percentage of participants
Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria)
percentage of participantsAlisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)
Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria)25234010050
SecondaryTime to Progression (TTP)

Time to progression (TTP) is defined as the time in days from the date of first study drug administration to the date of first documentation of Progressive Disease (PD) according to IWG criteria (Cheson 2007). PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.

Time frame:
Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years)
Reported as:
Median · days
Time to Progression (TTP)
daysAlisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)
Time to Progression (TTP)84.0 (48.0 to 430.0)139.0 (48.0 to 809.0)NA (NA to NA)NA (NA to NA)237.0 (46.0 to 631.0)
SecondaryProgression Free Survival (PFS)

PFS is defined as the time in days from the date of first study drug administration to the date of first documentation of progressive disease (PD) or death.

Time frame:
Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years)
Reported as:
Median · days
Progression Free Survival (PFS)
daysAlisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)
Progression Free Survival (PFS)84.0 (48.0 to 364.0)139.0 (48.0 to 809.0)NA (NA to NA)NA (NA to NA)237.0 (46.0 to 631.0)
SecondaryDuration of Response (DOR)

DOR is defined as the time from the date of first documentation of a CR, or partial response (PR) to the date of first documentation of PD according to IWG criteria. CR definition includes the complete disappearance of all evidence of disease, the definition of PR includes at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses, and PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir, as described in the IWG response criteria (Cheson 2007).

Time frame:
Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years)
Reported as:
Median · days
Duration of Response (DOR)
daysAlisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)
Duration of Response (DOR)454.0 (182.0 to 565.0)646.0 (243.0 to 646.0)NA (NA to NA)NA (NA to NA)596.0 (202.0 to 596.0)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and includes all-causality (ie, treatment-related and not treatment-related as assessed by the investigator).

Time frame:
First dose of study drug to 30 days after last dose (Up to 25 months)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events
participantsAlisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)
Number of Participants With Treatment-Emergent Adverse Events2213517
SecondaryNumber of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events

Vital signs (blood pressure, heart rate, and oral temperature) measurements were obtained throughout the study. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
First dose of study drug to 30 days after last dose (Up to 25 months)
Reported as:
Number · participants
Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events
participantsAlisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)
Pyrexia70002
Hypotension61101
Weight decreased21001
Tachycardia10002
Hypertension10000
Bradycardia10000
Cardiac flutter10000
SecondaryNumber of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events

Abnormal laboratory values for chemistry or hematology tests that were assessed by the investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE V4). A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
First dose of study drug to 30 days after last dose (Up to 25 months)
Reported as:
Number · participants
Number of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events
participantsAlisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)
Thrombocytopenia115315
Alanine aminotransferase increased60001
Aspartate aminotransferase increased60001
Blood alkaline phosphatase increased60001
Hypokalaemia30101
Blood lactate dehydrogenase increased30001
Blood creatinine increased00002
Blood potassium decreased10001
Lymphopenia10001
Blood urea increased10000
Hypercalcaemia00001
Hypernatraemia00001
Hypophosphataemia00001
Mean cell volume increased00001
Urine colour abnormal01000
Neutropenia139314

Adverse events

Collected over First dose of study drug to 30 days after last dose (Up to 25 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib 50 mg BID Starting Dose (DLBL)—16/22 (72.7%)22/22 (100%)
Alisertib 50 mg BID Starting Dose (MCL)—4/13 (30.8%)13/13 (100%)
Alisertib 50 mg BID Starting Dose (TFL)—5/5 (100%)5/5 (100%)
Alisertib 50 mg BID Starting Dose (BL)—0/1 (0%)1/1 (100%)
Alisertib 50 mg BID Starting Dose (ATL)—4/7 (57.1%)7/7 (100%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventAlisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)
Febrile NeutropeniaBlood and lymphatic system disorders6/220/130/50/11/7
NeutropeniaBlood and lymphatic system disorders3/222/131/50/11/7
PneumoniaInfections and infestations3/220/131/50/10/7
CellulitisInfections and infestations0/220/131/50/10/7
OsteomyelitisInfections and infestations0/220/131/50/10/7
Oropharyngeal candidiasisInfections and infestations0/220/131/50/10/7
Escherichia bacteraemiaInfections and infestations0/220/131/50/10/7
Hallucination, visualPsychiatric disorders0/220/131/50/10/7
DyspnoeaRespiratory, thoracic and mediastinal disorders0/220/131/50/10/7
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders0/220/131/50/10/7
Most frequent other events
Showing 10 of 160
Most frequent other events
EventAlisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)
NeutropeniaBlood and lymphatic system disorders16/229/134/51/14/7
AnaemiaBlood and lymphatic system disorders15/227/133/51/15/7
LeukopeniaBlood and lymphatic system disorders13/228/133/51/14/7
ThrombocytopeniaBlood and lymphatic system disorders10/225/133/51/15/7
DiarrhoeaGastrointestinal disorders14/228/133/51/13/7
StomatitisGastrointestinal disorders7/222/132/51/13/7
AlopeciaSkin and subcutaneous tissue disorders9/228/134/51/11/7
Rash erythematousSkin and subcutaneous tissue disorders0/220/130/51/10/7
SomnolenceNervous system disorders9/224/132/51/15/7
Decreased appetiteMetabolism and nutrition disorders7/222/130/51/13/7

Baseline characteristics

Safety population was defined as all participants who received any amount of alisertib.

Age, Continuous
Age, Continuous(years)Alisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)Total
Mean66.8 ± 11.1167.2 ± 6.7165.2 ± 9.9676.0 ± NA54.4 ± 16.9065.1 ± 11.56
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)Total
Female9130013
Male131221735
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)Total
White211351747
Other100001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Alisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)Total
Hispanic or Latino101013
Not Hispanic or Latino211341645
Weight
Weight(kg)Alisertib 50 mg BID Starting Dose (DLBL)Alisertib 50 mg BID Starting Dose (MCL)Alisertib 50 mg BID Starting Dose (TFL)Alisertib 50 mg BID Starting Dose (BL)Alisertib 50 mg BID Starting Dose (ATL)Total
Mean88.85 ± 27.02296.18 ± 25.13989.06 ± 29.72472.58 ± NA84.45 ± 14.49489.88 ± 24.737
08

Study locations

1 site
  • Hematology Oncology Associates, Virtua Memorial Hospital Burlington County
    Mount Holly, New Jersey 08060, United States
09

References and documents

Publications

  • Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22. PubMed 17242396 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2009 to primary completion in Jan 2011, 22 months.

Results were first posted in Mar 2018, 7 years 2 months after primary completion. A results delay was requested in Jun 2012.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 22 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2008
First posted
Dec 12, 2008
StartActual
Feb 10, 2009
Primary completionActual
Jan 4, 2011
CompletionActual
Feb 13, 2013
Results delay requested
Jun 19, 2012
Results first posted
Mar 27, 2018
Last update
Mar 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00807495
Responsible party
Sponsor
First posted
Dec 12, 2008
Start date
Feb 10, 2009
Primary completion
Jan 4, 2011
Completion
Feb 13, 2013
Results posted
Mar 27, 2018
Last update
Mar 27, 2018

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion